MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zhang, Guang jun ^a   Zhou, He ^a   Xiao, Hua xu ^a   Li, Yu ^a   Zhou, Tong ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Colorectal cancer; Invasion; miR 378; Prognosis; Vimentin

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 378; UNCLASSIFIED DRUG; VIMENTIN; 3' UNTRANSLATED REGION; MIRN378 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ASSAY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN RNA BINDING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BINDING SITE; CELL PROLIFERATION; CHEMISTRY; COLORECTAL TUMOR; DISEASE MODEL; GENETICS; METABOLISM; METASTASIS; MOLECULAR GENETICS; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HETEROGRAFTS; HUMANS; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE; TUMOR BURDEN; VIMENTIN;

EID: 84898601450     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-109     Document Type: Article

References (30)

1. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009, 18(6):1688-1694. 10.1158/1055-9965.EPI-09-0090, 19505900.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66. 10.3322/canjclin.57.1.43, 17237035.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
4. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005, 122(1):6-7. 10.1016/j.cell.2005.06.036, 16009126.
5. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005, 65(9):3509-3512. 10.1158/0008-5472.CAN-05-0298, 15867338.
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838. 10.1038/nature03702, 15944708.
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103(7):2257-2261. 10.1073/pnas.0510565103, 1413718, 16461460.
8. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008, 105(36):13556-13561. 10.1073/pnas.0803055105, 2528872, 18768788.
9. Steele CW, Oien KA, McKay CJ, Jamieson NB. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas 2011, 40(8):1165-1171. 10.1097/MPA.0b013e3182218ffb, 22001830.
10. Wu ZS, Wang CQ, Xiang R, Liu X, Ye S, Yang XQ, Zhang GH, Xu XC, Zhu T, Wu Q. Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 2012, 12:51. 10.1186/1471-2407-12-51, 3297527, 22292984.
11. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010, 23(4):1229-1234.
12. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, Svoboda M, Vyzula R, Slaby O. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012, 10:55. 10.1186/1479-5876-10-55, 3340316, 22440013.
13. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 2007, 104(51):20350-20355. 10.1073/pnas.0706901104, 2154434, 18077375.
14. Chen LT, Xu SD, Xu H, Zhang JF, Ning JF, Wang SF. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med Oncol 2012, 29(3):1673-1680. 10.1007/s12032-011-0083-x, 22052152.
15. Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J, Giguere V. miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab 2010, 12(4):352-361. 10.1016/j.cmet.2010.09.002, 20889127.
16. Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L, Guo J. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 2013, 518(2):351-359. 10.1016/j.gene.2012.12.103, 23333942.
17. Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM, Pierotti MA, Daidone MG, Canevari S, De Cecco L. Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS One 2012, 7(9):e45105. 10.1371/journal.pone.0045105, 3441572, 23028787.
18. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R, Slaby O. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012, 16(11):2655-2666. 10.1111/j.1582-4934.2012.01579.x, 22469014.
19. Mosakhani N, Sarhadi VK, Borze I, Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P, Knuutila S. MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer 2012, 51(1):1-9. 10.1002/gcc.20925, 21922590.
20. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010, 11(1):50-54. 10.1111/j.1751-2980.2009.00413.x, 20132431.
21. Garofalo M, Croce CM. microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 2011, 51:25-43. 10.1146/annurev-pharmtox-010510-100517, 20809797.
22. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428. 10.1172/JCI39104, 2689101, 19487818.
23. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005, 179(1-2):56-65.
24. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T, Brabletz T. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006, 131(3):830-840. 10.1053/j.gastro.2006.06.016, 16952552.
25. Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 2007, 313(10):2050-2062. 10.1016/j.yexcr.2007.03.040, 17512929.
26. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008, 68(10):3645-3654. 10.1158/0008-5472.CAN-07-2938, 18483246.
27. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2012, 62(9):1315-1326.
28. Shirahata A, Sakata M, Sakuraba K, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, Hibi K. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res 2009, 29(1):279-281.
29. McInroy L, Määttä A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun 2007, 360(1):109-114. 10.1016/j.bbrc.2007.06.036, 17585878.
30. Ngan CY, Yamamoto H, Seshimo I, Tsujino T, Man-i M, Ikeda JI, Konishi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer 2007, 96(6):986-992. 10.1038/sj.bjc.6603651, 2360104, 17325702.